Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the 2022 ASCO Annual Meeting
  • CME

June 3-7, 2022; Chicago, Illinois
Review expert perspectives on the most clinically relevant data on colorectal, hepatobiliary, and pancreatic cancers presented at the 2022 ASCO Annual Meeting.
Christopher H. Lieu, MD
Rachna Shroff, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: August 31, 2022 Expiration: August 30, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with gastrointestinal cancers
  • Identify subpopulations of patients with gastrointestinal cancers most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Evaluate new data on novel agents and therapeutic approaches for patients with gastrointestinal cancers

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research

Division of Medical Oncology
University of Colorado Cancer Center
Co-Director
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

Christopher H. Lieu, MD: researcher: Merck.
Rachna Shroff, MD

Assistant Professor of Medicine
Chief
, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Rachna Shroff, MD: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, CAMI, Clovis, Genentech, Incyte, Servier, QED, Zymeworks; researcher: Bayer, Bristol-Myers Squibb, Exelixis, IMV, Loxo, Merck, Novocure, Nucana, Pieris, QED, Rafael, Seagen, Taiho.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant financial relationships to disclose.
Julie Hicks, PhD
Julie Hicks, PhD, has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant financial relationships to disclose.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant financial relationships to disclose.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant financial relationships to disclose.
Brian Purves, PharmD, MBA
Brian Purves, PharmD, has no relevant financial relationships to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with gastrointestinal cancers.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with gastrointestinal cancers.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 31, 2022, through August 30, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable clinical resource with practical guidance on preventative care plans for transgender patients, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: October 7, 2022

Expert analysis module on key data from ESMO World GI 2022 in gastrointestinal cancers, from Clinical Care Options (CCO)

Joleen Hubbard, MD Rachna Shroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: October 4, 2022 Expired: October 3, 2023

An expert nurse practitioner provides guidance on strategies for developing compassionate care plans with transgender patients based on their current anatomy

person default Lauren Radziejewski, DNP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 4, 2022 Expired: October 3, 2023

Download this expert slideset on strategies for developing compassionate care plans with transgender patients based on their current anatomy

person default Lauren Radziejewski, DNP Released: October 4, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings